# Metreleptin in Anorexia Nervosa

> **NCT06305182** · PHASE2 · RECRUITING · sponsor: **Gabriella Milos** · enrollment: 50 (estimated)

## Conditions studied

- Anorexia Nervosa

## Interventions

- **DRUG:** Metreleptin
- **DRUG:** Sodium chloride

## Key facts

- **NCT ID:** NCT06305182
- **Lead sponsor:** Gabriella Milos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-31
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305182, "Metreleptin in Anorexia Nervosa". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06305182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*